{"id":21574,"date":"2025-01-15T12:08:00","date_gmt":"2025-01-15T04:08:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21574"},"modified":"2025-01-15T12:08:02","modified_gmt":"2025-01-15T04:08:02","slug":"eli-lilly-to-acquire-scorpion-therapeutics-stx-478-for-2-5b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21574","title":{"rendered":"Eli Lilly to Acquire Scorpion Therapeutics&#8217; STX-478 for $2.5B"},"content":{"rendered":"\n<p>US-based pharmaceutical giant Eli Lilly and Company (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3K\u03b1 inhibitor currently being studied in a Phase I\/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move aims to expand Eli Lilly&#8217;s oncology portfolio and enhance its capabilities in targeted therapies.<\/p>\n\n\n\n<p><strong>Acquisition Terms and Financials<\/strong><br>Under the terms of the agreement, Eli Lilly will acquire Scorpion Therapeutics, and Scorpion&#8217;s shareholders could receive up to USD 2.5 billion in cash. This includes an upfront payment and subsequent payments upon the achievement of certain regulatory and sales milestones. The transaction is structured to provide significant value to Scorpion&#8217;s shareholders while aligning with Eli Lilly&#8217;s strategic objectives.<\/p>\n\n\n\n<p><strong>Spin-Out of New Entity<\/strong><br>As part of the transaction, Scorpion will spin out a new entity to hold its employees and non-PI3K\u03b1 pipeline assets. The new, independent company will be owned by Scorpion&#8217;s current shareholders, with Eli Lilly holding a minority equity interest. This spin-out allows Scorpion to focus on its other promising assets while providing Eli Lilly with exclusive access to STX-478, a key asset in the development of targeted cancer therapies.<\/p>\n\n\n\n<p><strong>Strategic Implications for Eli Lilly<\/strong><br>The acquisition of STX-478 represents a significant step forward in Eli Lilly&#8217;s commitment to developing innovative therapies for patients with advanced cancers. By integrating STX-478 into its pipeline, Eli Lilly aims to accelerate the development of new treatment options and improve patient outcomes in breast cancer and other solid tumors. This move underscores Eli Lilly&#8217;s ongoing efforts to invest in and bring forward transformative medicines to the market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":21575,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,911,2958],"class_list":["post-21574","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-eli-lilly","tag-nyse-lly","tag-scorpion-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly to Acquire Scorpion Therapeutics&#039; STX-478 for $2.5B - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3K\u03b1 inhibitor currently being studied in a Phase I\/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move aims to expand Eli Lilly&#039;s oncology portfolio and enhance its capabilities in targeted therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21574\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly to Acquire Scorpion Therapeutics&#039; STX-478 for $2.5B\" \/>\n<meta property=\"og:description\" content=\"US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3K\u03b1 inhibitor currently being studied in a Phase I\/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move aims to expand Eli Lilly&#039;s oncology portfolio and enhance its capabilities in targeted therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21574\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-15T04:08:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-15T04:08:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1507.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"719\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly to Acquire Scorpion Therapeutics&#8217; STX-478 for $2.5B\",\"datePublished\":\"2025-01-15T04:08:00+00:00\",\"dateModified\":\"2025-01-15T04:08:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574\"},\"wordCount\":295,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1507.png\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Scorpion Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21574#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21574\",\"name\":\"Eli Lilly to Acquire Scorpion Therapeutics' STX-478 for $2.5B - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1507.png\",\"datePublished\":\"2025-01-15T04:08:00+00:00\",\"dateModified\":\"2025-01-15T04:08:02+00:00\",\"description\":\"US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3K\u03b1 inhibitor currently being studied in a Phase I\\\/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move aims to expand Eli Lilly's oncology portfolio and enhance its capabilities in targeted therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21574\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1507.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1507.png\",\"width\":1080,\"height\":719,\"caption\":\"Eli Lilly to Acquire Scorpion Therapeutics' STX-478 for $2.5B\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21574#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly to Acquire Scorpion Therapeutics&#8217; STX-478 for $2.5B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly to Acquire Scorpion Therapeutics' STX-478 for $2.5B - Insight, China&#039;s Pharmaceutical Industry","description":"US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3K\u03b1 inhibitor currently being studied in a Phase I\/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move aims to expand Eli Lilly's oncology portfolio and enhance its capabilities in targeted therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21574","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly to Acquire Scorpion Therapeutics' STX-478 for $2.5B","og_description":"US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3K\u03b1 inhibitor currently being studied in a Phase I\/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move aims to expand Eli Lilly's oncology portfolio and enhance its capabilities in targeted therapies.","og_url":"https:\/\/flcube.com\/?p=21574","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-15T04:08:00+00:00","article_modified_time":"2025-01-15T04:08:02+00:00","og_image":[{"width":1080,"height":719,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1507.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21574#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21574"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly to Acquire Scorpion Therapeutics&#8217; STX-478 for $2.5B","datePublished":"2025-01-15T04:08:00+00:00","dateModified":"2025-01-15T04:08:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21574"},"wordCount":295,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21574#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1507.png","keywords":["Eli Lilly","NYSE: LLY","Scorpion Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21574#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21574","url":"https:\/\/flcube.com\/?p=21574","name":"Eli Lilly to Acquire Scorpion Therapeutics' STX-478 for $2.5B - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21574#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21574#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1507.png","datePublished":"2025-01-15T04:08:00+00:00","dateModified":"2025-01-15T04:08:02+00:00","description":"US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3K\u03b1 inhibitor currently being studied in a Phase I\/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move aims to expand Eli Lilly's oncology portfolio and enhance its capabilities in targeted therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21574#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21574"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21574#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1507.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1507.png","width":1080,"height":719,"caption":"Eli Lilly to Acquire Scorpion Therapeutics' STX-478 for $2.5B"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21574#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly to Acquire Scorpion Therapeutics&#8217; STX-478 for $2.5B"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1507.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21574"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21574\/revisions"}],"predecessor-version":[{"id":21576,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21574\/revisions\/21576"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21575"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}